Generic placeholder image

Current Molecular Medicine


ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Research Article

Diagnostic Value of MiR-125b as a Potential Biomarker for Stage I Lung Adenocarcinoma

Author(s): Arife Zeybek*, Necdet Öz, Serdar Kalemci, Tuba Edgünlü, Mehmet Tuğhan Kızıltuğ, Kürşad Tosun, Mustafa Tunç, Leyla Tekin and Mehmet Emin Erdal

Volume 19 , Issue 3 , 2019

Page: [216 - 227] Pages: 12

DOI: 10.2174/1566524019666190314113800

Price: $65


Background: We aimed at exploring biological functions of differentially expressed miRNAs during carcinogenesis, to identify miRNAs dysegulations involved in DNA repair mechanisms, and to evaluate potential of miRNAs as prognostic and diagnostic biomarkers for early lung adenocarcinomas (LAC).

Methods: We obtained 21 LAC and paired adjacent normal formalin-fixed, paraffinembedded lung tissues from patients who underwent curative resection for stage I LAC. We compared expression levels of eight miRNAs involved in the DNA repair mechanism between LAC and adjacent tissues.

Results: Expressions of Hsa-miR-9-5p, hsa-miR-24-3p, hsa-miR-125a-3p, hsa-miR- 125b-5p, hsa-miR-155-5p, and hsa-let-7a-5p were significantly up-regulated in stage I LAC tissues compared with those in the adjacent tissues. In addition, expressions of hsa-mir-9-5p, hsa-mir-24-3p, hsa-mir-125a-3p, hsa-mir-125b-5p, and hsa-mir-155-5p were significantly up-regulated in stage Ia LAC tissues, whereas expressions of hsa-mir- 125a-3p and hsa-mir-125b-5p were significantly up-regulated in stage Ib LAC tissues. Receiver operating characteristic (ROC) analysis revealed that AUROC of hsa-mir-125b- 5p was 0.875 (P < 0.001).

Conclusion: Expression of hsa-mir-125b-5p could be used to distinguish LAC from adjacent tissues. Our result suggests that hsa-mir125b-5p can be a prognostic and diagnostic biomarker for LAC.

Keywords: Carcinoma, non-small cell lung cancer, adenocarcinoma, Micro RNA, Mir-125b, biomarkers.

Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
Kong YW, McCollough FD, Jackson TJ, Bushell M. MicroRNAs in cancer management. Lancet Oncol 2012; 13: e249-58.
Travis WD, Brambilla E, Burke AP, Marx A, Nicholson AG. WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart, 4th ed.; IARC: Lyon, France, 2015.
The Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543-50.
Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
Inamura K, Ishikawa Y. MicroRNA in lung cancer: Novel biomarkers and potential tools for treatment. J Clin Med 2016; 5: 36.
Booton R, Lindsay MA. Emerging role of microRNAs and long noncoding RNAs in respiratory disease. Chest 2014; 146: 193-204.
Matikas A, Syrigos KN, Agelaki S. Circulating biomarkers in non-small-cell lung cancer: Current status and future challenges. Clin Lung Cancer 2016; 17: 507-16.
Erdal ME, Yılmaz SG, Gürgül S, Uzun C, Derici D, Erdal N. miRNA expression profile is altered differentially in the rat brain compared to blood after experimental exposure to 50 Hz and 1 mT electromagnetic field. Prog Biophys Mol Biol 2018; 132: 35-42.
Agarwal V, Bell GW, Nam J, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 2015; 12e05005
Ashburner M, Ball CA, Blake JA, et al. Gene ontology: a tool for the unification of biology. Nat Genet 2000; 25: 25-9.
Kanehisa FM, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases, and drugs. Nucleic Acids Res 2017; 45: 353-61.
Szklarczyk D, Morris JH, Cook H, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017; 45: 362-8.
Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-504.
Nakamura H, Saji H. Worldwide trend of increasing primary adenocarcinoma of the lung. Surg Today 2014; 44: 1004-12.
Lin PY, Yu SL, Yang PC. MicroRNA in lung cancer. Br J Cancer 2010; 103: 1144-8.
Yang H, Luo J, Liu Z, Zhou R, Luo H. MicroRNA-138 regulates DNA damage response in small cell lung cancer cells by directly targeting H2AX. Cancer Invest 2015; 33: 126-36.
Zhong Z, Dong Z, Yang L, Chen X, Gong Z. MicroRNA-31-5p modulates cell cycle by targeting human mutL homolog 1 in human cancer cells. Tumour Biol 2013; 34: 1959-65.
Zhong Z, Dong Z, Yang L, Gong Z. miR-21 induces cell cycle at S phase and modulates cell proliferation by down-regulating hMSH2 in lung cancer. J Cancer Res Clin Oncol 2012; 138: 1781-8.
Yamashita S, Chujo M, Tokuishi M, Anami K, Miyawaki M, Yamamoto S. Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma. J Thorac Cardiovasc Surg 2009; 138: 1303-8.
Chang CC, Shih JY, Jeng YM, et al. Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. J Natl Cancer Inst 2004; 96: 364-7.
Kristof J, Sakrison K, Xiaoping Jin, et al. Real-time reverse-transcription quantitative polymerase chain reaction assay is a feasible method for the relative quantification of heregulin expression in non-small cell lung cancer tissue. Biomark Insights 2017; 121177271917699850
Ishikawa M, Sonobe M, Imamura N, Sowa T, Shikuma K, Date H. Expression of the GLI family genes is associated with tumor progression in advanced lung adenocarcinoma. World J Surg Oncol 2014; 12: 253.
Hyun J, Chulwon L, Lee KSG, Yanga WM, Uma JY. Ophiopogonin D modulates multiple oncogenic signaling pathways, leading to suppression of proliferation and chemosensitization of human lung cancer cells. Phytomedicine 2018; 40: 165-75.
Liu W, Ma W, Yuan Y, Zhang Y, Sun S. Circular RNA hsa_circRNA_103809 promotes lung cancer progression via facilitating ZNF121-dependent MYC expression by sequestering miR-4302. Biochem Biophys Res Commun 2018; 500: 846-51.
Ye J, Zhang Z, Sun L, Fang Y, Xu X, Zhou G. MiR-186 regulates chemo-sensitivity to paclitaxel via targeting MAPT in non-small cell lung cancer (NSCLC). Mol Biosyst 2016; 12: 3417-24.
Zanetti KA, Wang Z, Aldrich M, Amos CI, Blot WJ, Bowman ED. Genome-wide association study confirms lung cancer susceptibility loci on chromosome 5p15 and 15q25 in an African-American population. Lung Cancer 2016; 98: 33-42.
Brammell JS, Petljak M, Martincorena I, Williams SP, Alonso LG, Dalmases A. Genome-wide chemical mutagenesis screens allow unbiased saturation of the cancer genome and identification of drug resistance mutations. Genome Res 2017; 27: 613-25.
Zoncu R, Sabatini MD, Efeyan A. mTOR: from growth signal integration to cancer, diabetes, and ageing. Nat Rev Mol Cell Biol 2011; 12: 21-35.
Peng Z, Pan L, Niu Z, Li W, Dang X, Wan L, et al. Identification of microRNAs as potential biomarkers for lung adenocarcinoma using integrating genomics analysis. Oncotarget 2017; 8: 64143-56.
Tian Z, Wen S, Zhang Y, et al. Identification of dysregulated long non-coding RNAs/ microRNAs/mRNAs in TNM I stage lung adenocarcinoma. Oncotarget 2017; 8: 51703-18.
Guo K, Jin F. NFAT5 promotes proliferation and migration of lung adenocarcinoma cells in part through regulating AQP5 expression. Biochem Biophys Res Commun 2015; 465: 644-9.
Koscielny G, An P, Silva CD, Cham JA, Gasparyan LF. Open Targets: a platform for therapeutic target identification and validation. Nucleic Acids Res 2017; 45: 985-94.
Nishida N, Yokobori T, Mimori K, Sudo T, Tanaka F, Shibata K, et al. MicroRNA miR-125b is a prognostic marker in human colorectal cancer. Int J Oncol 2011; 38: 1437-43.
Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. J Cancer Res Clin Oncol 2012; 138: 2045-50.
Cui E, Li H, Hua F, Wang B, Mao W, Feng X. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol Sin 2013; 34: 309-13.

Rights & Permissions Print Export Cite as
© 2022 Bentham Science Publishers | Privacy Policy